Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
MELBOURNE, Australia, May 17, 2023 -- Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced... | May 17, 2023
Source: marketscreener.com